Bronchogen Protocol: Complete Cycling & Dosing Guide
Bronchogen is a short-chain tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed to support respiratory epithelial tissue function and regeneration. Unlike pharmaceutical bronchodilators or corticosteroids that provide symptomatic relief, Bronchogen works as a gene expression regulator—it penetrates cell nuclei and interacts with DNA promoter regions to normalize transcription patterns in bronchial and pulmonary epithelial cells.
The primary mechanism involves restoring homeostatic signaling in aged or damaged bronchial tissue by upregulating pathways that govern mucociliary clearance, epithelial integrity, ciliary function, and local immune defense. This makes it relevant for individuals managing COPD, chronic bronchitis, recurrent respiratory infections, or age-related decline in lung capacity.
Important: Bronchogen is not FDA-approved and is sold as a dietary supplement or research compound in most Western countries. This guide is educational. Consult a physician before use, especially if you have active respiratory malignancies, autoimmune pulmonary diseases, or are on immunosuppressive therapy.
- Daily Dose: 10–20 mg per day
- Frequency: Once daily (morning preferred)
- Routes: Sublingual or oral
- Typical Supply: 10 mg capsules
| Route | Dose | Timing | Advantages | Disadvantages |
|---|
| Sublingual | 10–20 mg | Morning, empty stomach | Faster tissue contact; minimal GI breakdown | Localized irritation; less convenient |
| Oral | 10–20 mg | With or without food | More convenient; better tolerability | Slower onset; some GI metabolism |
Standard respiratory support cycle:
- On-Cycle: 30 days (continuous daily dosing)
- Assess Period: 7–14 days off-cycle (evaluate response)
- Off-Cycle: 7–14 days minimum rest before next cycle
- Repeat: Up to 3–4 cycles per year for maintenance
This pattern allows tissue-level adaptation without continuous exposure and helps you identify genuine response signals.
Objective: Restore bronchial epithelial structure, reduce inflammation, enhance mucociliary clearance
Dosing:
- 20 mg daily (two 10 mg capsules sublingual or oral)
- Morning administration
Cycle:
- Initial Phase: 60 days continuous (allows epithelial remodeling time)
- Rest: 14 days off
- Repeat: 2–3 cycles, then assess necessity
Expected Timeline:
- Week 2–3: Possible mild increase in mucus production (sign of epithelial normalization)
- Week 4–6: Reduced bronchospasm frequency, improved morning sputum clearance
- Week 8+: Improved exercise tolerance, reduced infection rate in subsequent months
Stack Option: Combine with N-acetylcysteine (NAC) 600 mg twice daily for enhanced mucolytic effect.
Objective: Support local immune function via elevated secretory IgA, maintain epithelial barrier integrity
Dosing:
- 10 mg daily (single 10 mg capsule)
- Morning, with light food to minimize transient nausea
Cycle:
- Primary Cycle: 30 days continuous
- Maintenance Phase: 10 mg every other day for 30 days
- Rest: 30 days off
- Repeat: Seasonal use (autumn/winter) or year-round if recurrence pattern is significant
Expected Timeline:
- Week 2–3: Stabilization of upper respiratory mucosa
- Week 4–6: Reduced infection incidence (typically observed after cycle completion)
- Month 2+: Decreased severity of infections if breakthrough occurs
Stack Option: Combine with quercetin 500 mg twice daily for synergistic mucosal immune support.
Objective: Stimulate tissue-specific gene expression in aged bronchial epithelium, restore ciliary function
Dosing:
- 10–15 mg daily (one 10 mg capsule + one 5 mg dose, or split dosing)
- Morning and evening divided dosing may enhance tissue contact
Cycle:
- Primary Cycle: 45 days continuous
- Rest: 30 days off
- Repeat: 2 cycles per year (spring and autumn)
Expected Timeline:
- Week 3–4: Possible mild transient fatigue (epigenetic remodeling effect)
- Week 6–8: Improved baseline oxygen saturation during normal activity
- Week 10+: Enhanced exercise capacity, reduced dyspnea during stairs/inclines
Stack Option: Combine with CoQ10 300 mg daily for mitochondrial support in aging lung tissue.
- Preparation: Take capsule on empty stomach or 30 minutes before food
- Capsule Opening: Open 10 mg capsule and place powder under tongue
- Holding Time: Keep sublingual for 3–5 minutes without swallowing
- Saliva Management: Allow saliva to pool; swallow naturally after holding period
- Recovery Time: Wait 15 minutes before eating or drinking
- Frequency: Once daily (morning optimal for monitoring side effects)
Tips:
- If localized tingling occurs, reduce holding time to 2 minutes on first use
- Ensure tongue is clean and dry before administration
- Stay hydrated throughout the day
- Preparation: Can take with or without food
- Capsule Intact: Swallow 10 mg capsule whole with water
- Timing: Morning preferred for consistency and to avoid sleep disruption
- Food Pairing: If nausea occurs, take with light breakfast (toast, fruit)
- Frequency: Once daily; maintain consistent timing
Tips:
- Oral absorption is slower but GI side effects are minimal
- Consistency in timing aids protocol tracking
- Do not split capsules if using capsule form; open only for sublingual use
| Week | Dosing | Notes |
|---|
| Week 1 | 10 mg daily, morning sublingual | Monitor for mild nausea or sublingual irritation; baseline respiratory function assessment |
| Week 2 | 10 mg daily, morning sublingual | Expected: possible increase in mucus production (positive sign); continue as-is |
| Week 3 | Increase to 20 mg (two capsules) if tolerated | Split into morning sublingual for faster onset |
| Week 4 | 20 mg daily, morning sublingual | Continue; most users report symptom improvements by this point |
| Week 5–6 (if 60-day cycle) | 20 mg daily, maintain | Monitor for plateau or continued improvement |
| Week 7–8 (if 60-day cycle) | 20 mg daily, maintain | Final phase of epithelial remodeling |
| Post-Cycle Days 1–14 | OFF (0 mg daily) | Rest and assessment period; note subjective changes |
| Post-Cycle Days 15+ | Evaluate before repeating | Decide on repeat cycle based on response |
- Most Common: No noticeable change; possible mild transient nausea if taken on empty stomach
- Occasional: Mild sublingual tingling or irritation (sublingual route)
- Positive Sign: Increased mucus production (indicates epithelial turnover beginning)
- Expected: Gradual reduction in chronic cough frequency
- Likely: Improved morning sputum clearance quality
- Possible: Enhanced ability to clear mucus with lighter effort
- Variable: Mood or energy changes (usually neutral; rarely positive)
Longer-Term (Weeks 5–8, Post-Cycle Weeks 1–4)
- Primary Outcome: Reduced infection rate, improved baseline spirometry or 6-minute walk distance
- Secondary Outcome: Decreased dyspnea during exertion
- Sustained Effect: Benefits often continue or improve after cycle completion during rest phase (delayed epigenetic effect)
- Some individuals see no subjective change but have improved objective markers (e.g., improved sputum clearance on exam)
- If no change by week 6, consider:
- Extended cycle (8 weeks instead of 4) before conclusion
- Protocol adherence verification
- Possible individual variability in epigenetic response
- Error: Skipping days or dosing at random times
- Impact: Reduces tissue-level accumulation; delays or prevents response
- Fix: Use daily alarm; keep pills in consistent location; log each dose
- Error: Expecting results in week 1–2
- Impact: Incorrect conclusion of non-responsiveness
- Fix: Commit to full 30–60 day cycle before assessing; record baseline measurements
- Error: Staying at 10 mg when protocol allows 20 mg
- Impact: Subtherapeutic tissue concentrations; minimal effect
- Fix: Follow escalation schedule (10 mg for 1–2 weeks, then increase to 20 mg if tolerated)
- Error: Dosing daily indefinitely without off-cycles
- Impact: Possible tolerance development; no assessment period
- Fix: Follow 30/14 or 60/14 on/off structure; assess during rest periods
- Error: Taking Bronchogen with high-dose immunosuppressants simultaneously
- Impact: Potential contraindication; unclear interaction effects
- Fix: Consult physician if on immunosuppressive therapy; separate timing by 2+ hours if approved
- Error: Storing capsules in humid bathroom or direct sunlight
- Impact: Peptide degradation; reduced potency
- Fix: Store at room temperature (15–25°C), dry, away from light
Bronchogen works through epigenetic tissue-specific signaling, making it compatible with most respiratory support compounds. However, avoid simultaneous high-dose immune suppression without medical clearance.
Stack 1: Enhanced Mucolytic & Anti-Inflammatory (COPD)
- Bronchogen 20 mg daily
- N-Acetylcysteine (NAC) 600 mg twice daily
- Timing: Bronchogen morning sublingual, NAC with breakfast and lunch
- Rationale: NAC enhances mucus thinning; Bronchogen restores epithelial structure
- Duration: Concurrent throughout Bronchogen cycle
Stack 2: Immune Restoration (Recurrent Infections)
- Bronchogen 10 mg daily
- Quercetin 500 mg twice daily
- Zinc picolinate 15 mg daily
- Timing: Bronchogen morning, quercetin with meals, zinc evening
- Rationale: Quercetin supports mucosal barrier; Bronchogen increases IgA; zinc sustains immune cells
- Duration: Concurrent throughout cycle
Stack 3: Aging Lung Function (Age-Related Decline)
- Bronchogen 10–15 mg daily (split morning/evening if possible)
- CoQ10 ubiquinol 300 mg daily
- Alpha-lipoic acid 300 mg daily
- Timing: Bronchogen morning and evening, CoQ10 + ALA with meals
- Rationale: CoQ10 supports mitochondrial function in aging tissues; ALA provides antioxidant support
- Duration: Concurrent; extended cycles (45 days) recommended
| Compound | Issue | Recommendation |
|---|
| High-dose corticosteroids (oral) | May suppress epithelial immune remodeling | Physician consultation required |
| Immunosuppressants (azathioprine, mycophenolate) | Theoretical risk of adverse interaction with tissue remodeling | Avoid without medical supervision |
| Antitussive agents (codeine, dextromethorphan) | May suppress beneficial mucus clearance during epithelial restoration | Use only if approved by physician |
| Parameter | Standard | COPD/Bronchitis | Infection Prevention | Age-Related Decline |
|---|
| Dose | 10–20 mg/day | 20 mg/day | 10 mg/day | 10–15 mg/day |
| Route | Sublingual or oral | Sublingual (faster) | Oral (tolerability) | Sublingual or split |
| On-Cycle | 30 days | 60 days | 30 days | 45 days |
| Off-Cycle | 14 days | 14 days | 30 days | 30 days |
| Repeats/Year | 3–4 cycles | 2 cycles | 1–2 cycles | 2 cycles |
| Cost/Month | $30–80 | $60–160 | $30–80 | $40–100 |
| Primary Goal | Respiratory support | Epithelial restoration | Immune function | Function recovery |
| Timeline to Effect | 4–8 weeks | 4–8 weeks | Post-cycle | 6–10 weeks |
- Reduced frequency of spontaneous cough (morning or throughout day)
- Improved quality/ease of sputum production (less viscous, easier clearance)
- Increased baseline oxygen saturation during normal activity (if measured)
- Reduced number of respiratory infections in subsequent seasons
- Improved exercise tolerance (less dyspnea on stairs or exertion)
- Enhanced morning energy (secondary effect, some users)
Increase dose from 10 mg to 20 mg if:
- No subjective or objective improvement by week 3–4
- Excellent tolerability with no adverse effects
- Baseline respiratory impairment is moderate-to-severe
Extend cycle from 30 to 60 days if:
- Positive response noted but plateau not yet reached by week 4
- Participant is managing COPD or chronic bronchitis
- Medical supervision confirms safety
Stop and reassess if:
- Persistent allergic-type reaction (rash, swelling, breathing difficulty beyond baseline)
- Severe, unrelenting nausea despite timing/food adjustments
- Unexplained deterioration in respiratory function
- Active diagnosis of respiratory malignancy (contraindication)
- Temperature: Room temperature (15–25°C)
- Light: Keep in original opaque container; avoid direct sunlight
- Humidity: Store in dry environment (not bathroom); use desiccant packs if available
- Shelf Life: Typically 12–24 months from manufacture (verify expiration date)
- Handling: Avoid exposure to moisture; do not open capsules until immediately before use (if sublingual)
This protocol guide is educational content only and does not constitute medical advice, diagnosis, or treatment recommendation. Bronchogen is not FDA-approved or EMA-approved and is sold as a dietary supplement or research compound.
Before starting any Bronchogen protocol, consult a qualified healthcare provider, especially if you:
- Have active respiratory malignancy
- Carry diagnoses of autoimmune pulmonary disease
- Take immunosuppressive medications
- Are pregnant, breastfeeding, or have significant comorbidities
- Have a history of peptide hypersensitivity or allergic reactions
The evidence base for Bronchogen derives primarily from animal models and in-vitro studies. Limited independent human clinical trial data exist outside the originating Russian research institute. Individual responses vary significantly. Users assume full responsibility for their decision to use Bronchogen and any outcomes thereof.
Last Updated: Protocol information reflects available scientific literature. Verify current research status and product regulations in your jurisdiction before purchase or use.